Background: PD-1 pathway blockade has revolutionized cancer care, but many patients do not durably benefit from these therapies. Novel treatments to engage anti-tumor immunity in this setting are need
Although ACVR2A mutations are prevalent in non-viral hepatocellular carcinomas (HCC), the underlying mechanism remains unelucidated. Our molecular investigation reveals that ACVR2A impairment induces
Supplementary Table from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
